Operator
Good day, and thank you for standing by. Welcome to the QTORIN docetaxel for Extramammary Paget’s Disease Conference Call. [Operator Instructions] Please be advised that today’s conference is being recorded.
I would now like to hand the conference over to your speaker today, Bohan Wei, Vice President of Corporate Development and New Product Planning. Please go ahead.
Bohan Wei
Vice President of Corporate Development & New Product Planning
Thank you, operator. Good morning, and thank you for joining the Palvella Therapeutics conference call to discuss our new product candidate, QTORIN docetaxel for Extramammary Paget’s Disease. As a reminder, our press release detailing today’s announcements can be found in the Investors section of our website at www.palvellatx.com.
Before we begin, please note that today’s remarks may include forward-looking statements regarding our development programs, regulatory strategy, commercial planning and financial outlook. These statements are based on current assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Please refer to our SEC filings for a full discussion of these risk factors.
The format of today’s conference call will be presentation only. Additionally, as a reminder, we will not be discussing or commenting on our ongoing clinical trials.
On today’s call, we are joined by Wes Kaupinen, Palvella’s Founder and Chief Executive Officer; Dr. Jeff Martini, our Chief Scientific Officer; Dr. David Osborne, our Chief Innovation Officer; Dr. Seemal Desai, Founder of Innovative Dermatology and Faculty at the University of Texas Southwestern Medical Center; and Steve Schroeder, an EMPD patient and founder
Credit: Source link























